Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials

BACKGROUND: Using a machine learning approach, the study investigated if specific baseline characteristics could predict which psoriatic arthritis (PsA) patients may gain additional benefit from a starting dose of secukinumab 300 mg over 150 mg. We also report results from individual patient efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Alice B., Mease, Philip J., Kirkham, Bruce, Nash, Peter, Balsa, Alejandro C., Combe, Bernard, Rech, Jürgen, Zhu, Xuan, James, David, Martin, Ruvie, Ligozio, Gregory, Abrams, Ken, Pricop, Luminita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389345/
https://www.ncbi.nlm.nih.gov/pubmed/32015257
http://dx.doi.org/10.1097/RHU.0000000000001302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389345/
https://www.ncbi.nlm.nih.gov/pubmed/32015257
http://dx.doi.org/10.1097/RHU.0000000000001302

Ejemplares similares